Cargando…

Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy

Mucopolysaccharidosis is a rare disease and can be divided into seven different subtypes, according to the affected enzyme. Mucopolysaccharidosis type I, the first subtype discovered and reported, mainly affects the in vivo storage of degraded sugar. The current treatment methods are symptomatic the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ying, Liu, Deyun, Yu, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010773/ https://www.ncbi.nlm.nih.gov/pubmed/35433540 http://dx.doi.org/10.3389/fped.2022.823044

Ejemplares similares

α-L-iduronidase therapy for mucopolysaccharidosis type I
por: Tolar, Jakub, et al.
Publicado: (2008)

Insights into Mucopolysaccharidosis I from the structure and action of α-L-Iduronidase
por: Bie, Haiying, et al.
Publicado: (2013)

Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
por: Kida, Sachiho, et al.
Publicado: (2023)

Three novel α-L-iduronidase mutations in 10 unrelated Chinese mucopolysaccharidosis type I families
por: Sun, Luning, et al.
Publicado: (2011)

Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-L-iduronidase mutations in Tunisian patients
por: Chkioua, Latifa, et al.
Publicado: (2011)

A novel p.E276K IDUA mutation decreasing α-L-iduronidase activity causes mucopolysaccharidosis type I
por: Prommajan, Korrakot, et al.
Publicado: (2011)

Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report
por: Vasilevska, Lauma, et al.
Publicado: (2022)

Mesenchymal Stem Cells Do Not Prevent Antibody Responses against Human α-L-Iduronidase when Used to Treat Mucopolysaccharidosis Type I
por: Martin, Priscila Keiko Matsumoto, et al.
Publicado: (2014)

Report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I
por: Kwak, Min Jung, et al.
Publicado: (2016)

Genotypic and bioinformatic evaluation of the alpha-l-iduronidase gene and protein in patients with mucopolysaccharidosis type I from Colombia, Ecuador and Peru
por: Pineda, Tatiana, et al.
Publicado: (2014)

Comment on “report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I”
por: Poletto, Edina, et al.
Publicado: (2018)

Alpha‐L‐iduronidase deficiency: A novel mutation resulting in severe early presentation of Mucopolysaccharidosis type I and literature review of the molecular basis
por: Al Zaabi, Nuha Nasser, et al.
Publicado: (2022)

Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I
por: Grant, Nathan, et al.
Publicado: (2021)

New Irreversible α‐l‐Iduronidase Inhibitors and Activity‐Based Probes
por: Artola, Marta, et al.
Publicado: (2018)

A Simple and Rapid Method Based on Liquid Chromatography-Tandem Mass Spectrometry for the Measurement of α-L-Iduronidase Activity in Dried Blood Spots: An Application to Mucopolysaccharidosis I (Hurler) Screening
por: Yang, Jeong Soo, et al.
Publicado: (2015)

Case Report: Diagnosis of Mucopolysaccharidosis Type IVA With Compound Heterozygous Galactosamine-6 Sulfatase Variants and Biopsy of Replaced Femoral Heads
por: Ma, Yiyang, et al.
Publicado: (2022)

Development of a newborn screening tool for mucopolysaccharidosis type I based on bivariate normal limits: Using glycosaminoglycan and alpha‐L‐iduronidase determinations on dried blood spots to predict symptoms
por: Langan, Thomas J., et al.
Publicado: (2020)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Mucopolysaccharidosis Type I Diagnosed by Aortic and Mitral Valve Replacement
por: Sherwood, Dalton J., et al.
Publicado: (2021)

Quantitative Analysis of α-L-Iduronidase Expression in Immunocompetent Mice Treated with the Sleeping Beauty Transposon System
por: Aronovich, Elena L., et al.
Publicado: (2013)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014)

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I
por: Le, Steven Q., et al.
Publicado: (2017)

Chiari I malformation and syringomyelia in mucopolysaccharidosis type I (Hurler syndrome) treated with posterior fossa decompression: Case report and review of the literature
por: Makler, Vyacheslav, et al.
Publicado: (2017)

Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
por: Hsu, Yu-Hone, et al.
Publicado: (2017)

Characterization and downstream mannose phosphorylation of human recombinant α-L-iduronidase produced in Arabidopsis complex glycan-deficient (cgl) seeds
por: He, Xu, et al.
Publicado: (2013)

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial
por: Giugliani, Roberto, et al.
Publicado: (2018)

The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis
por: Qu, Yuhua, et al.
Publicado: (2022)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system
por: Kim, Sarah, et al.
Publicado: (2022)

Bull's eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy
por: Mack, Heather G., et al.
Publicado: (2017)

Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
por: Sugiura, Kenta, et al.
Publicado: (2020)

Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
por: Hampe, Christiane S., et al.
Publicado: (2021)

Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): a case report
por: Andrade, Isadora, et al.
Publicado: (2022)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Long-term evolution of mucopolysaccharidosis type I in twins treated with enzyme replacement therapy plus hematopoietic stem cells transplantation
por: Carbajal-Rodríguez, Luis M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qmsouid4rmh8d4aq4a0d8dr4k9